Your AI-Trained Oncology Knowledge Connection!
SAN ANTONIO-A pharmaceutical alternative to prophylactic oophorectomy as a means of inducing menopause and reducing the likelihood of breast cancer in young women at high genetic risk is under investigation at the City of Hope National Medical Center.
WASHINGTON-Surgeons in community hospitals as well as in university-based cancer centers can successfully find sentinel lymph nodes (SLNs) in breast cancer patients for biopsy, Douglas S. Reintgen, MD, of the H. Lee Moffitt Cancer Center, University of South Florida, Tampa, said at the 54th Annual Cancer Symposium of the Society of Surgical Oncology (SSO).
SAN ANTONIO-Fulvestrant (Faslodex), an estrogen-receptor (ER) downregulator (see Figure), appears to be at least as good as the aromatase inhibitor anastrozole (Arimidex) as second-line therapy in postmenopausal women with advanced breast cancer who had progressed or recurred on prior endocrine therapy.
CHICAGO-Magnetic resonance imaging (MRI) mammography was able to detect eight of nine breast malignancies, some of which had been missed on conventional film mammography, in 196 young women at high risk for hereditary breast cancer.
The 3rd Investigators’ Workshop, sponsored by The University of Texas M. D. Anderson Cancer Center, included five separate scientific sessions. The topics covered were colorectal carcinoma, lung carcinoma, breast carcinoma, miscellaneous
SAN ANTONIO-The gonadotropin hormone-releasing hormone agonist analog goserelin (Zoladex) is an alternative to adjuvant chemotherapy for women with early breast cancer who are pre- or perimenopausal and have estrogen-receptor (ER)-positive tumors, said Walter Jonat, MD, of the University of Kiel, Germany. He spoke at the 23rd Annual San Antonio Breast Cancer Symposium on behalf of the Zoladex Early Breast Cancer Research Association (ZEBRA).
Anecdotal reports of cognitive compromise among patients treated with chemotherapy are relatively common among breast cancer survivors and may play an important role in adversely affecting functioning in multiple domains. As noted by Dr. Olin,
Dr. Julie Olin has highlighted an important issue for patients and providers contemplating systemic therapy for breast cancer: how the brain works after such treatment. Her excellent article summarizes four important studies, identifies the research design problems and questions raised by these and other studies, and proposes a model for how chemohormonal therapy might affect cognitive functioning and quality of life (see Figure 1 of her article). Finally, she identifies how actual, as well as potential, cognitive impairment might influence patient decisions and care (the author’s Table 1).
Several trials have shown that anthracyclines and taxanes can be combined to achieve response rates ranging from 70% to 90%, with complete responses ranging from 19% to 41%. In an attempt to increase the activity while
Recently initiated is a phase III randomized trial (MA.21 trial) of adjuvant chemotherapy for node-positive and high-risk node-negative, premenopausal and postmenopausal (£ 60 years) women with breast cancer who have
Doxorubicin/paclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high incidence of cardiotoxicity. A phase I/II trial replacing
The aromatase inhibitors represent an important class of hormonal agents for the management of breast cancer. The third-generation aromatase inhibitors have replaced megestrol acetate as second-line hormonal
Tamoxifen (Nolvadex) has long been established as "standard" adjuvant therapy for receptor-positive, early-stage breast cancer. Results from clinical trials suggest that after approximately 5 years, tamoxifen may lose its
An underinvestigated area of breast cancer survivorship involves the possible impairment of cognitive function following adjuvant chemohormonal therapy. Numerous reports of disturbing and disruptive changes in short- and
Several attempts have been made to improve the survival rates of breast cancer patients. The benefit of adjuvant chemotherapy was clearly shown, but the absolute difference of 2% to 11% in overall survival, depending on the
According to data presented at the American Society of Hematology (ASH) meeting and the San Antonio Breast Cancer Symposium, elderly cancer patients may be up to two times as likely as younger patients to receive chemotherapy doses
FORT LAUDERDALE, Florida-A panel of breast cancer experts has revised the National Comprehensive Cancer Network (NCCN) breast cancer guideline to reflect an evolution rather than change. "The differences between this and last year’s guidelines are overall meaningful but subtle," Robert W. Carlson, MD, of Stanford Hospitals and Clinics, said at the Sixth Annual NCCN Conference.
SAN ANTONIO-By using a system combining color-based imaging and automated microscopy, pathologists were able to significantly improve their accuracy in evaluating HER-2 protein expression in breast cancer tissue, said Kenneth Bloom, MD, of Rush-Presbyterian-St. Luke’s Medical Center, Chicago.
NEW YORK-The jury may still be out on the value of adjuvant paclitaxel (Taxol) for early breast cancer (see article on page 3 on the updated NCCN breast cancer guideline), but a study from M.D. Anderson suggests it may have a small
WASHINGTON-Despite some promising new technologies, traditional x-ray film mammography remains the gold standard in screening for breast cancer, a committee of the Institute of Medicine (IOM) has concluded.
Medical researchers at the 23rd annual San Antonio Breast Cancer Symposium reported the results of a study showing that automated cell imaging adapted from Star Wars missile-
In response to the increasing use of sentinel lymphadenectomy, a panel convened by the American Society of Breast Surgeons has issued a revised consensus statement on performance and utilization criteria for sentinel lymphadenectomy.
BETHESDA, Md-A study of breast cancer patients with hereditary BRCA1 and BRCA2 mutations or sporadic cancers has shown a distinctive gene-expression profile for each type of breast cancer gene mutation and also revealed an unanticipated finding-a patient with a nonhereditary BRCA1 mutation.
BETHESDA, Md-General Motors Corp. is mailing information on the opportunity for a breast cancer risk assessment, available through the Study of Tamoxifen and Raloxifene (STAR), to 140,000 of its active and retired salaried female
The article by Dr. William Small on the role of radiation therapy in the treatment of breast cancer is a comprehensive review of the current standards of care and highlights the controversies surrounding recent trends. Breast cancer treatment has come full circle in the last 20 years, with emphasis now being placed on technical advances and treatment techniques as new data substantiate the impact of radiation therapy on survival following local surgery and mastectomy.
